Open AccessThe influence of pioglitazon on hemostasis and proteolysis in patients with essential hypertension combined with diabetes mellitus of type 2
Author(s) -
S. V. Biletskyi,
O. A. Petrynich,
Т. В. Казанцева
Publication year - 2013
Publication title -
bukovinsʹkij medičnij vìsnik
Language(s) - English
Resource type - Journals
eISSN - 2413-0737
pISSN - 1684-7903
DOI - 10.24061/2413-0737.xvii.1.65.2013.4
Subject(s) - metformin , lisinopril , medicine , fibrinolysis , type 2 diabetes mellitus , hemostasis , diabetes mellitus , fibrinogen , amlodipine , essential hypertension , pharmacology , endocrinology , blood pressure , angiotensin converting enzyme
The authors have examined 30 patients with essential hypertension combined with diabetes mellitus of type 2 in the dynamics of treating with a combination of antihypertensive agents (S-amlodipine and lisinopril) with metformin or pioglitazon. It has been established that treating with antihypertensive drugs with metformin and pioglitazon is accompanied with a significant decrease of the fibrinogen level, an elevated activity of antitrhombin III and Hagemann’s dependent fibrinolysis, an increase of the potential activity of plasminogen (in the subgroup of metformin), a decrease of the indices of the lysis of low- and high-molecular proteins without changes of the blood collagenolytic activity.